We have located links that may give you full text access.
Oncogenes expand during evolution to withstand somatic amplification.
Annals of Oncology : Official Journal of the European Society for Medical Oncology 2018 September 12
Background: Cancer-related genes are under intense evolutionary pressure. We conjectured that gene size is an important determinant of amplification propensity for oncogenes and thus cancer susceptibility and therefore could be subject to natural selection.
Patients and Methods: Gene information, including size and genomic locations, of all protein-coding genes were downloaded from Ensembl (release 87). Quantification of gene amplification was based on GISTIC scores obtained from available The Cancer Genome Atlas studies.
Results: Oncogenes are larger in size as compared with non-cancer genes (mean size: 92.1 kb vs 61.4 kb; p < 0.0001) in the human genome, which is contributed by both increased total exon size (mean size: 4.6 kb vs 3.4 kb; p < 0.0001) and higher intronic content (mean %: 84.8 vs 78.0; p < 0.01). Such non-random size distribution and intronic composition are conserved in mouse and Drosophila (all p-values < 0.0001). Stratification by gene age indicated that young oncogenes have been subject to a stronger evolutionary pressure for gene expansion than their non-cancer counterparts. Pan-cancer analysis demonstrated that larger oncogenes were amplified to a lesser extent. Tumor-suppressor genes also moved towards small oncogenes in the course of evolution.
Conclusions: Oncogenes expand in size whereas tumor-suppressor genes move closer to small oncogenes in the course of evolution to withstand oncogenic somatic amplification. Our findings have shed new light on the previously unappreciated influence of gene size on oncogene amplification and elucidated how cancers have shaped our genome to its present configuration.
Patients and Methods: Gene information, including size and genomic locations, of all protein-coding genes were downloaded from Ensembl (release 87). Quantification of gene amplification was based on GISTIC scores obtained from available The Cancer Genome Atlas studies.
Results: Oncogenes are larger in size as compared with non-cancer genes (mean size: 92.1 kb vs 61.4 kb; p < 0.0001) in the human genome, which is contributed by both increased total exon size (mean size: 4.6 kb vs 3.4 kb; p < 0.0001) and higher intronic content (mean %: 84.8 vs 78.0; p < 0.01). Such non-random size distribution and intronic composition are conserved in mouse and Drosophila (all p-values < 0.0001). Stratification by gene age indicated that young oncogenes have been subject to a stronger evolutionary pressure for gene expansion than their non-cancer counterparts. Pan-cancer analysis demonstrated that larger oncogenes were amplified to a lesser extent. Tumor-suppressor genes also moved towards small oncogenes in the course of evolution.
Conclusions: Oncogenes expand in size whereas tumor-suppressor genes move closer to small oncogenes in the course of evolution to withstand oncogenic somatic amplification. Our findings have shed new light on the previously unappreciated influence of gene size on oncogene amplification and elucidated how cancers have shaped our genome to its present configuration.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app